Why the study?
ACS carries substantial residual risk driven by inflammation and lipid dysregulation, motivating the evaluation of serum ACSL1, ACSL3, ATF3, and CH25H as clinically applicable biomarkers for ACS diagnosis and prognosis.
Population
517 consecutive suspected ACS patients undergoing coronary angiography (including 387 confirmed ACS patients)
Comparison
Serum levels of ACSL1, ACSL3, ATF3, and CH25H
Follow-up
Through April 2026
Answers are grounded in this paper and cite their sources.
These biomarkers may aid ACS diagnosis/prognosis; leaves open validation before precision-medicine adoption.
Background ACS remains a leading global cause of cardiovascular death despite standard care, with residual risk driven by inflammation and lipid dysregulation promoting plaque instability. We evaluated ACSL1, ACSL3, ATF3, and CH25H as clinically applicable biomarkers for ACS diagnosis and prognosis within inflammation‐focused precision medicine. Methods This study consecutively enrolled 517 suspected ACS patients undergoing coronary angiography. The primary endpoint was MACEs during follow‐up through April 2026. Biomarker performance was evaluated by ROC curves, multivariable logistic regression (for ACS diagnosis), and Cox proportional hazards models (for MACE prognosis). Results All four biomarkers ACSL1, ACSL3, ATF3, and CH25H demonstrated good discriminatory performance for predicting MACEs, with areas under the curve of 0.720 (95% confidence interval [CI]: 0.650–0.790), 0.712 (95% CI: 0.639–0.786), 0.617 (95% CI: 0.537–0.697), and 0.727 (95% CI: 0.655–0.798), respectively. After adjusting for age, sex, and conventional risk factors, multivariable logistic regression showed each biomarker independently associated with ACS. Trend and restricted cubic spline analyses linked higher levels to increased ACS likelihood. Among the 387 patients with ACS, 107 (27.6%) experienced MACEs during follow‐up, including 9 deaths and 98 rehospitalizations. Multivariable Cox regression analysis identified high ACSL1, ACSL3, CH25H, and ATF3 levels as independent predictors of MACEs, with hazard ratios of 1.896 (95% CI: 1.116–3.220), 1.986 (95% CI: 1.203–3.278), 2.447 (95% CI: 1.155–5.183), and 7.284 (95% CI: 3.720–14.263), respectively. Higher levels of these biomarkers were further linked to a higher rehospitalization risk. Restricted cubic spline analyses revealed that increasing levels of ACSL1, ACSL3, CH25H, and ATF3 were related to an increased risk of MACEs. Conclusions Serum ACSL1, ACSL3, ATF3, and CH25H are independent diagnostic and prognostic biomarkers for ACS, reflecting intertwined lipid‐metabolic and inflammatory pathways. They enable refined risk stratification for postdischarge adverse events, supporting precision medicine targeting inflammation and lipid dysregulation in ACS.
No takes yet. Share an insight, caveat, or question.
Bu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: